8-K: Acasti Pharma Advances GTX-104 for Brain Hemorrhage Treatment, Targeting $300M US Market

Acasti Pharma is developing GTX-104, an intravenous nimodipine formulation, to address the limitations of oral nimodipine in treating aneurysmal subarachnoid hemorrhage (aSAH), with a Phase 3 trial underway and a potential NDA submission in 2025.

Summary

• Acasti Pharma is focused on developing GTX-104, a novel intravenous formulation of nimodipine, for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).
• The current standard of care, oral nimodipine, has limitations due to variable absorption, difficulty in administration to unconscious patients, and side effects like hypotension.
• GTX-104 aims to overcome these limitations with its intravenous delivery, offering 100% bioavailability compared to the 7% bioavailability of oral nimodipine.
• A Phase 1 trial demonstrated that GTX-104 achieved comparable pharmacokinetics to oral nimodipine at approximately 1/12th of the dose.
• The company has initiated a Phase 3 safety trial called STRIVE-ON, with a potential NDA submission planned for the first half of 2025.
• The US market opportunity for aSAH treatment is estimated to be over $300 million annually, with potential for expansion into EU and China.
• Acasti's cash balance of $25.1 million as of December 31, 2023, is expected to fund the STRIVE-ON trial and potential NDA filing.
• The company has a strong patent portfolio with patents extending to 2042 and has received orphan drug designation from the FDA.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Acasti Pharma, highlighting the potential of GTX-104 and the progress of the Phase 3 trial. However, it also acknowledges the risks and uncertainties associated with drug development and regulatory approval.

Positives

• GTX-104 offers a more predictable and consistent drug concentration compared to oral nimodipine.
• The intravenous formulation of GTX-104 overcomes the limitations of oral administration, such as variable absorption and difficulty in administering to unconscious patients.
• The Phase 1 trial demonstrated a successful pharmacokinetic bridge with oral nimodipine, paving the way for the Phase 3 trial.
• The company has a strong intellectual property portfolio with patents extending to 2042.
• GTX-104 has the potential to reduce medication errors, nursing burden, and rescue therapy, leading to shorter ICU stays and improved patient outcomes.
• The company has a clear regulatory pathway with a de-risked NDA filing process requiring only one safety trial.

Negatives

• The document highlights the challenges with the current standard of care, oral nimodipine, including variable absorption, difficulty in administration, and side effects like hypotension.
• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for GTX-104.
• The document mentions that actual results and the timing of events could differ materially from those anticipated due to various risks and uncertainties.

Risks

• The success and timing of regulatory submissions for the Phase 3 safety trial of GTX-104 are uncertain.
• Regulatory requirements or developments and the outcome of the proposed NDA application for GTX-104 are subject to change.
• Changes to clinical trial designs and regulatory pathways could impact the development timeline.
• Legislative, regulatory, political, and economic developments could affect the company's operations.
• Actual costs associated with Acasti's clinical trials may differ from management's current expectations.
• The company's cash runway is projected into Q2 2026, but future funding needs may arise.

Future Outlook

Acasti anticipates a potential NDA submission for GTX-104 in the first half of 2025 and expects its current cash balance to fund the STRIVE-ON trial and the NDA filing process. The company is also evaluating partnering strategies for commercialization.

Management Comments

• The company is focused on disrupting the standard of care for aSAH treatment with GTX-104.
• Management believes GTX-104 is well-positioned to solve the challenges associated with oral nimodipine.
• The company is evaluating partnering strategies opportunistically for commercialization.

Industry Context

Acasti's development of GTX-104 addresses a significant unmet need in the treatment of aSAH, where the current standard of care, oral nimodipine, has limitations. The company is targeting a large market opportunity with a novel intravenous formulation that offers improved bioavailability and predictable drug concentrations.

Comparison to Industry Standards

• The current standard of care for aSAH is oral nimodipine, which has limitations in terms of bioavailability (~7%) and administration, particularly in unconscious patients.
• Acasti's GTX-104 aims to improve upon this by offering 100% bioavailability through intravenous administration, potentially leading to more predictable and effective treatment.
• Other companies developing treatments for aSAH include those focused on surgical interventions and other drug therapies, but Acasti's approach with an improved nimodipine formulation is unique.
• The market for aSAH treatment is estimated at $300 million in the US, indicating a significant opportunity for Acasti if GTX-104 is approved.

Stakeholder Impact

• Shareholders may benefit from the potential success of GTX-104 and the company's growth.
• Patients with aSAH may have access to a more effective treatment option.
• Hospitals may benefit from a more predictable and easier-to-administer treatment option.
• Employees may benefit from the company's growth and success.

Next Steps

• Continue enrollment in the STRIVE-ON Phase 3 trial.
• Prepare for a potential NDA submission in the first half of 2025.
• Evaluate partnering strategies for commercialization.
• Continue building the patent portfolio by filing for patent protection on new developments.

Key Dates

Keywords

GTX-104, nimodipine, aSAH, subarachnoid hemorrhage, intravenous, Phase 3 trial, NDA, bioavailability, orphan drug, pharmaceutical